share_log

Avalo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Avalo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Avalo Therapeutics | PRE 14A：并购重组委托声明
美股sec公告 ·  06/07 07:06
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has announced its upcoming Annual Meeting, which will be conducted virtually via live audio webcast on an unspecified date in 2024. The meeting will address several key corporate matters, including the election of seven directors nominated by the board for a one-year term, approval of common stock issuance for various purposes, and the ratification of Ernst & Young LLP as the company's independent accounting firm for the fiscal year ending December 31, 2024. Additionally, stockholders will vote on the approval of the Fourth Amended and Restated Equity Incentive Plan and the Amended and Restated Employee Stock Purchase Plan, both of which propose to increase available shares and extend automatic annual increases. The company will also seek authorization to adjourn the meeting if necessary to solicit additional votes.
Avalo Therapeutics, Inc. has announced its upcoming Annual Meeting, which will be conducted virtually via live audio webcast on an unspecified date in 2024. The meeting will address several key corporate matters, including the election of seven directors nominated by the board for a one-year term, approval of common stock issuance for various purposes, and the ratification of Ernst & Young LLP as the company's independent accounting firm for the fiscal year ending December 31, 2024. Additionally, stockholders will vote on the approval of the Fourth Amended and Restated Equity Incentive Plan and the Amended and Restated Employee Stock Purchase Plan, both of which propose to increase available shares and extend automatic annual increases. The company will also seek authorization to adjourn the meeting if necessary to solicit additional votes.
Avalo Therapeutics, Inc. 宣布将于2024年未定日期通过实时音频网络直播形式举行年度股东大会。会议将涉及多项主要企业事宜，包括选举董事会提名的七位董事担任一年任期、核准发行普通股以供各种用途，并批准安永会计师事务所作为公司独立会计师审计2024年12月31日结束的财政年度。此外，股东们还将就第四次修订后的股权激励计划以及修订后的员工股票购买计划进行投票，两者均计划增加可用股份并延长年度自动增加期限。公司还将寻求授权以在必要时休会以征求更多的票数。
Avalo Therapeutics, Inc. 宣布将于2024年未定日期通过实时音频网络直播形式举行年度股东大会。会议将涉及多项主要企业事宜，包括选举董事会提名的七位董事担任一年任期、核准发行普通股以供各种用途，并批准安永会计师事务所作为公司独立会计师审计2024年12月31日结束的财政年度。此外，股东们还将就第四次修订后的股权激励计划以及修订后的员工股票购买计划进行投票，两者均计划增加可用股份并延长年度自动增加期限。公司还将寻求授权以在必要时休会以征求更多的票数。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息